Key regions: Germany, United States, France, China, Canada
The Anti-Hypertensive Drugs market in Argentina has been experiencing steady growth in recent years, driven by various factors.
Customer preferences: Argentinian customers tend to prefer generic drugs over branded ones due to their affordability. This trend is also observed in the Anti-Hypertensive Drugs market, where generic drugs are more popular than branded drugs. Additionally, customers are increasingly seeking drugs with fewer side effects and more convenient dosing schedules.
Trends in the market: The Anti-Hypertensive Drugs market in Argentina is expected to continue growing due to the increasing prevalence of hypertension in the country. The aging population, unhealthy lifestyles, and the rising incidence of obesity are contributing to the growing prevalence of hypertension. As a result, there is a growing demand for Anti-Hypertensive Drugs in the country.
Local special circumstances: Argentina's healthcare system is primarily public, with a significant portion of the population relying on the government for healthcare services. This has led to a focus on cost-effective treatments, including generic drugs. Additionally, the country has a well-established pharmaceutical industry that is capable of producing high-quality generic drugs at lower prices.
Underlying macroeconomic factors: Argentina's economy has been struggling in recent years, with high inflation rates and a devalued currency. This has made it difficult for pharmaceutical companies to import raw materials and manufacture drugs, leading to supply chain disruptions and shortages. However, the government has taken steps to address these issues, including implementing price controls on drugs and increasing investment in the pharmaceutical industry.In conclusion, the Anti-Hypertensive Drugs market in Argentina is expected to continue growing due to the increasing prevalence of hypertension in the country. However, the market is also subject to various challenges, including supply chain disruptions and shortages due to the country's struggling economy. Despite these challenges, the country's focus on cost-effective treatments and a well-established pharmaceutical industry bode well for the future of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
